Elagolix is an FDA-approved treatment for moderate-to-severe pain associated with endometriosis but has been associated with increased acute porphyric attacks in women with the acute hepatic porphyrias (AHPs). A fluorescence-based screening assay for drug porphyrogenicity in LMH cells indicates that elagolix is porphyrogenic; thus, elagolix should be avoided or used with caution in patients with the AHPs.
Keywords: Acute hepatic porphyrias; Acute porphyric attack; Elagolix; Endometriosis; Fluorescence-based screening assay; Gastroenterology; Hepatology; OBGYN; Porphyrogenic.
© 2022 The Authors. Published by Elsevier Inc.